Actuate Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Actuate Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-41.8%

Buyback Yield

Total Shareholder Yield	-41.8%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Jul 29

Actuate: Elraglusib Continues To Deliver And Next Catalyst Is FDA Type B Meeting

Summary Actuate Therapeutics' elraglusib combo showed strong phase 2 results in 1st-line metastatic pancreatic cancer patients, improving survival and reducing disease progression. A major catalyst is the upcoming FDA Type B pre-NDA meeting, which could allow a faster regulatory path to U.S. marketing approval or require a phase 3 trial first. Despite promising data, significant financial risks and potential dilution remain, as current cash likely won't last past Q2 2025. I rate ACTU as 'Hold' until FDA feedback clarifies the approval path; a positive outcome from it could warrant a 'Buy' upgrade. Read the full article on Seeking Alpha

Seeking Alpha • Mar 26

Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer

Summary Actuate Therapeutics' lead drug, elraglusib, shows promise in early trials for pancreatic cancer but faces challenges like solubility issues and financial instability. The company's phase 2 trial showed improved survival rates with elraglusib, but the control arm underperformed, raising questions about future phase 3 results. ACTU's financials are concerning, with only $8.6 million in cash and a high burn rate, making future funding uncertain. Despite interesting early data, the significant risks and financial challenges make ACTU a risky investment at this time. Read the full article on Seeking Alpha

Analysis Article • Feb 12

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ACTU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACTU's dividend payments have been increasing.

Dividend Yield vs Market

Actuate Therapeutics Dividend Yield vs Market

How does ACTU dividend yield compare to the market?
Segment	Dividend Yield
Company (ACTU)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.3%
Industry Average (Biotechs)	2.4%
Analyst forecast (ACTU) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate ACTU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACTU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ACTU's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ACTU has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/20 06:45
End of Day Share Price	2026/05/20 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Actuate Therapeutics, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Mayank Mamtani	B. Riley Securities, Inc.
Gum-Ming Lowe	Craig-Hallum Capital Group LLC
Swayampakula Ramakanth	H.C. Wainwright & Co.

Actuate Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Actuate Therapeutics, Inc. Announces Appointment of Martin Huber as an Independent Director, Effective May 6, 2026

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Actuate Therapeutics, Inc., Annual General Meeting, May 21, 2026

Actuate Therapeutics, Inc. Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into A Phase 1/2 Clinical Program in Refractory Cancers

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-To-Treat Refractory Pediatric Cancers

Actuate Therapeutics, Inc. Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma

Actuate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA over the Coming Months

Actuate Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.000006 million.

Actuate Therapeutics, Inc. to Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Actuate: Elraglusib Continues To Deliver And Next Catalyst Is FDA Type B Meeting

Actuate Therapeutics, Inc. Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-To-Treat Pediatric Sarcomas

Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000E Value Index

Actuate Therapeutics, Inc. announced that it expects to receive $4.665479 million in funding

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

Actuate Therapeutics, Inc. Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Actuate Therapeutics, Inc. Shares Highlights from Kol Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics, Inc. Presents Topline Elraglusib Phase 2 Data At Asco 2025 Annual Meeting

Actuate Therapeutics, Inc. Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer

Actuate Therapeutics, Inc. Announces Completion of Patient Enrollment in Ongoing Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan for Undreated Metastatic Pancreatic Pancreatic Ductal Adenocarcinoma

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Invest In Growth?

Actuate Therapeutics, Inc., Annual General Meeting, May 22, 2025

Actuate Therapeutics, Inc. Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

Actuate Therapeutics, Inc. Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics, Inc. Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Actuate Therapeutics, Inc. has completed an IPO in the amount of $22.4 million.